new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp A Corporation A Subsidiary Of Merck x26 Co Inc
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors


N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof

Merck Sharp & Dohme Corp.

N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof



Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 Mono- and di-peg il-10 production; and uses
22015001159001/08/15 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12 Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12 Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52015020942407/30/15  new patent  Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
62015021068507/30/15  new patent  Novel azabenzimidazole tetrahydropyran derivatives
72015021068707/30/15  new patent  N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
82015020348707/23/15 Novel azabenzimidazole tetrahydrofuran derivatives
92015020349607/23/15 Aliphatic spirolactam cgrp receptor antagonists
102015020351207/23/15 Macrocyclic compounds as hiv integrase inhibitors
112015019749007/16/15 Crystalline polymorphic forms of an antidiabetic compound
122015019753107/16/15 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
132015019757007/16/15 Anti-ilt5 antibodies and ilt5-binding antibody fragments
142015019777207/16/15 Mammalian expression vector puhab
152015019040207/09/15 Solid dosage formulations of an orexin receptor antagonists
162015019143407/09/15 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
172015019146107/09/15 Pyrazolyl derivatives as syk inhibitors
182015019149507/09/15 Antidiabetic tricyclic compounds
192015018250307/02/15 Mineralocorticoid receptor antagonists
202015017553406/25/15 Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
212015017557506/25/15 Imidazolyl analogs as syk inhibitors
222015017560906/25/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
232015016648606/18/15 Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
242015016649006/18/15 Mineralocorticoid receptor antagonists
252015016652006/18/15 Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
262015015893506/11/15 Protective vaccine based on staphylococcus aureus sa2493 protein
272015015099006/04/15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
282015015212706/04/15 Permeable glycosidase inhibitors and uses thereof
292015014733705/28/15 Crystalline anti-human il-23 antibodies
302015014824605/28/15 Surface anchored light chain bait antibody display system
312015014832705/28/15 Substituted pyridine spleen tyrosine kinase (syk) inhibitors
322015013998605/21/15 Ilt3 binding molecules and uses therefor
332015014142805/21/15 Trka kinase inhibitors, compositions and methods thereof
342015014144405/21/15 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
352015012644305/07/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
362015012649305/07/15 Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
372015011939404/30/15 Insulin-like growth factor-1 receptor inhibitors
382015011186604/23/15 Cyclic amine substituted heterocyclic cetp inhibitors
392015011187704/23/15 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
402015011191404/23/15 Spirolactam cgrp receptor antagonists
412015010445304/16/15 Fdf03 antibodies and uses thereof
422015010446504/16/15 Il-19 as a biomarker of tslp treatment
432015010531704/16/15 Glucose-responsive insulin conjugates
442015010535404/16/15 Heterocyclic aspartyl protease inhibitors
452015009989104/09/15 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
462015009971504/09/15 Formulations of acadesine
472015009971904/09/15 Cathepsin cysteine protease inhibitors
482015009972904/09/15 Inhibitors of the renal outer medullary potassium channel
492015009977104/09/15 Pyridine cgrp receptor antagonists
502015009339804/02/15 Methods and compositions for treating or preventing cancer
512015008390603/26/15 Biomarkers for monitoring intervention therapies for diabetes
522015008764103/26/15 Heterocyclic cgrp receptor antagonists
532015008783203/26/15 Process for making beta 3 agonists and intermediates
542015007899603/19/15 Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
552015007903103/19/15 Use of pegylated il-10 to treat cancer
562015008059803/19/15 Asymmetric synthesis for preparing fluoroleucine alkyl esters
572015006419203/05/15 Mammalian cell surface antigens; related reagents
582015005619102/26/15 Igf1 biomarker for igf1r inhibitor therapy
592015005122702/19/15 Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
602015005124802/19/15 Imidazolyl methyl piperidine t-type calcium channel antagonists
612015004425002/12/15 Vaccines against clostridium difficile comprising recombinant toxins
622015004534602/12/15 Selective glycosidase inhibitors and uses thereof
632015004557502/12/15 Process for preparing fluoroleucine alkyl esters
642015003849002/05/15 Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
652015003849802/05/15 Thrombin inhibitors
662015003850202/05/15 Isoxazolopyridine orexin receptor antagonists
672015003870702/05/15 Process for making cgrp receptor antagonists
682015003171301/29/15 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
692015003171601/29/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
702015003189101/29/15 Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
712015002080601/22/15 Dry powder inhaler for delivering multipe agglomerate formulations
722015002395201/22/15 Anti-addl monoclonal antibody and uses thereof
732015002407101/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
742015002504601/22/15 Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
752015001768601/15/15 Methods for reducing mannosyltransferase activity in lower eukaryotes
762015001839901/15/15 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
772015001056401/08/15 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
782015000460801/01/15 Monocyte-derived nucleic acids and related compositions and methods
792015000533001/01/15 Piperidinone carboxamide azaindane cgrp receptor antagonists
802014037726012/25/14 Protective vaccine based on staphylococcus aureus sa2074 protein
812014037849312/25/14 Fused bicyclic oxazolidinone cetp inhibitor
822014037002512/18/14 Uses of mammalian cytokines and agonists; related reagents
832014037113812/18/14 Inhibitors of hepatitis c virus replication
842014034997211/27/14 Substituted pyrimidines
852014034884111/27/14 Anti-gitr antibodies
862014034999811/27/14 Pyrrolopyrimidines as janus kinase inhiitors
872014035000211/27/14 Imidazopyridin-2-one derivatives
882014034307111/20/14 Compositions and methods for treating cancer
892014033619611/13/14 Phosphoric acid salts of sitagliptin
902014032927611/06/14 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
912014032351910/30/14 Heterocyclic compounds as b-raf inhibitors for treatment of cancer
922014029620210/02/14 Substituted piperidinyl compounds useful as gpr119 agonists
932014029622110/02/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
942014029622210/02/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
952014027501709/18/14 Cgrp receptor antagonists
962014025681809/11/14 Nano-suspension process
972014024428908/28/14 Cold storage system for storing pharmaceutical product containers
982014023429608/21/14 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
992014023430108/21/14 Modulation of pilr to treat immune disorders
1002014023553708/21/14 N-glycosylated insulin analogues
1012014022562708/14/14 Device for calibrating and verifying the integrity of resistivity-based sensing probes
1022014022722308/14/14 Pegylated interleukin-10
1032014022725008/14/14 Stable formulations of antibodies to tslp
1042014022729008/14/14 Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
1052014022729208/14/14 Anti-mcam antibodies and associated methods of use
1062014022002708/07/14 1d05 pcsk9 antagonists
1072014022138308/07/14 Cetp inhibitors
1082014021241207/31/14 Use of il-33 antagonists to treat fibrotic disease
1092014020656307/24/14 Biomarkers for psoriasis
1102014020664007/24/14 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1112014020664107/24/14 Remedy
1122014020666507/24/14 Selective glycosidase inhibitors and uses thereof
1132014020667507/24/14 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1142014020671507/24/14 Preparation and use of compounds as protease inhibitors
1152014020018007/17/14 Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1162014020021307/17/14 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
1172014017015406/19/14 Engineered anti-il-23r antibodies
1182014017065806/19/14 Mammalian cytokines; related reagents
1192014017143706/19/14 Oxazole derivatives useful as inhibitors of faah
1202014017145606/19/14 Fused tricyclic compounds as mtor inhibitors
1212014017148006/19/14 Crystalline polymorphic forms of an antidiabetic compound
1222014016177006/12/14 2'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
1232014016179806/12/14 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
1242014014744205/29/14 Use of il-23 antagonists for treatment of infection
1252014014746105/29/14 Polypeptides for inducing a protective immune response against staphylococcus aureus
1262014014095405/22/14 Methods of modulating cytokine activity; related reagents
1272014014101205/22/14 Engineered anti-tslp antibody
1282014014144405/22/14 Isolated mammalian monocyte cell genes; related reagents
1292014014144505/22/14 Isolated mammalian monocyte cell genes; related reagents
1302014014211505/22/14 Inhibitors of the renal outer medullary potassium channel
1312014012836105/08/14 Cyclic amide bace-1 inhibitors having a benzamide substituent
1322014012836705/08/14 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
1332014012836805/08/14 Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
1342014012003705/01/14 Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
1352014011291904/24/14 Interleukin-10 antibodies
1362014011392004/24/14 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1372014010588704/17/14 Methods for modulating il-33 activity
1382014010641304/17/14 Immobilized transaminases and process for making and using immobilized transaminase
1392014010734604/17/14 Process for preparing chiral dipeptidyl peptidase-iv inhibitors
1402014009356404/03/14 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
1412014009387504/03/14 Mammalian cytokines; receptors; related reagents and methods
1422014008804803/27/14 Diazeniumdiolate cyclohexyl derivatives
1432014008088403/20/14 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
1442014005789302/27/14 Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
1452014005174002/20/14 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1462014004574602/13/14 Antidiabetic tricyclic compounds
1472014004582902/13/14 Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
1482014004583202/13/14 Insulin-like growth factor-1 receptor inhibitors
1492014003762702/06/14 Modulation of pilr receptors to treat microbial infections
1502014003894202/06/14 Rorgammat inhibitors
1512014003897002/06/14 Bridged and fused antidiabetic compounds
1522014003025501/30/14 Methods of predicting cancer cell response to therapeutic agents
1532014003076001/30/14 Pavec
1542014003125101/30/14 Methods of classifying human subjects with regard to cancer prognosis
1552014003134901/30/14 Inhibitors of the renal outer medullary potassium channel
1562014002366701/23/14 Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1572014000518201/02/14 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1582013034451212/26/13 Cd16a reporter assay for evaluation of adcc potential of biologics
1592013033137212/12/13 Cyclic amine substituted oxazolidinone cetp inhibitor
1602013032323912/05/13 Modulation of pilr receptors to treat sepsis
1612013032324612/05/13 Use of mdl-1 antagonists to treat spondylarthropathy
1622013032325112/05/13 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
1632013032448312/05/13 Mammalian cell surface antigens; related reagents
1642013032461012/05/13 Cathepsin cysteine protease inhibitors
1652013032472812/05/13 Process for the preparation of an orexin receptor antagonist
1662013031635411/28/13 Mammalian cytokine; related reagents
1672013029627811/07/13 Diazeniumdiolate derivatives
1682013028776310/31/13 Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1692013028021410/24/13 Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1702013028147410/24/13 Fused tricyclic inhibitors of mammalian target of rapamycin
1712013026114010/03/13 Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1722013025167709/26/13 Genetic markers associated with interferon-alpha response
1732013024369209/19/13 Fdg-pet evaluation of ewing's sarcoma sensitivity
1742013023751809/12/13 Novel compounds that are erk inhibitors
1752013023085509/05/13 Monocyte-derived nucleic acids and related compositions and methods
1762013022558208/29/13 Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1772013022583608/29/13 Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1782013021657508/22/13 Recombinant subunit dengue virus vaccine
1792013021769508/22/13 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1802013021775608/22/13 Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1812013021776608/22/13 Formulations for cathepsin k inhibitors
1822013020306008/08/13 Mammalian genes; related reagents
1832013018927807/25/13 Antagonists of pcsk9
1842013015794006/20/13 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1852013015672906/20/13 Mammalian receptor proteins; related reagents and methods
1862013015677106/20/13 Fdf03 antibodies and uses thereof
1872013015036206/13/13 Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1882013014385906/06/13 Novel prolylcarboxypeptidase inhibitors
1892013013104105/23/13 Spirocyclic compounds
1902013013104205/23/13 Spiroxazolidinone compounds
1912013012200905/16/13 Engineered anti-il-23p19 antibodies
1922013012320005/16/13 Mammalian cell surface antigens; related reagents
1932013012323705/16/13 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1942013011522305/09/13 Antagonists of pcsk9
1952013011623105/09/13 Tyrosine kinase inhibitors
1962013010973905/02/13 Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1972013009605304/18/13 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1982013007139003/21/13 Method for preparing antibodies having improved properties
1992013006481703/14/13 Engineered anti-il-23r antibodies
2002013005985003/07/13 Aza-indole derivatives useful as modulators of faah
2012013005335202/28/13 Diazeniumdiolate cyclopentyl derivatives
2022013004591402/21/13 Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
2032013004092902/14/13 Novel prolylcarboxypeptidase inhibitors
2042013004093202/14/13 Substituted aryl sulfone derivatives as calcium channel blockers
2052013003456102/07/13 Isolated mammalian monocyte cell genes; related reagents
2062013003531202/07/13 Cathepsin cysteine protease inhibiors
2072013002351501/24/13 Novel spiropiperidine prolylcarboxypeptidase inhibitors
2082013001804801/17/13 Oxazole derivatives useful as modulators of faah
2092013001252601/10/13 Oxazole derivatives useful as modulators of faah
2102013000579701/03/13 Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
2112013000451801/03/13 Cyclic amine bace-1 inhibitors having a benzamide substituent
2122012032967912/27/12 Eukaryotic cell display systems
2132012031532112/13/12 Immunological methods and compositions for the treatment of alzheimer's disease
2142012031620012/13/12 Pyridone derivatives
2152012027724011/01/12 Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
2162012026477710/18/12 Oxadiazole beta carboline derivatives as antidiabetic compounds
2172012023200709/13/12 Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
2182012023208609/13/12 Fused tricyclic compounds with adenosine a2a receptor antagonist activity
2192012022588609/06/12 Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2202012021484608/23/12 Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2212012021484708/23/12 2-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
2222012020188508/09/12 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
2232012019690108/02/12 Tertiary amide orexin receptor antagonists
2242012019070107/26/12 Renin inhibitors
2252012017868107/12/12 Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
2262012017875007/12/12 Niacin receptor agonists, compositions containing such compounds and methods of treatment
2272012017239707/05/12 Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2282012016415806/28/12 Anti-addl monoclonal antibody and use thereof
2292012015743806/21/12 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
2302012015743206/21/12 Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2312012014277006/07/12 Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
2322012014269406/07/12 Substituted 4-hydroxypyrimidine-5-carboxamides
2332012014275206/07/12 Hiv protease inhibitors
2342012013601205/31/12 Amino tetrahydro-pyridopyrimidine pde10 inhibitors
2352012012162405/17/12 Hepatitis c virus ns3 protease inhibitors
2362012011913005/17/12 Diaphragm valve with improved sealing performance and leak detection
2372012012150805/17/12 Radiolabeled cgrp antagonists
2382012012158005/17/12 Methods for producing high concentration lyophilized pharmaceutical formulations
2392012012289905/17/12 Piperidinone carboxamide azaindane cgrp receptor antagonists
2402012012290005/17/12 Piperidinone carboxamide azaindane cgrp receptor antagonists
2412012012291105/17/12 Piperidinone carboxamide azaindane cgrp receptor antagonists
2422012011589405/10/12 Imidazole derivatives useful as modulators of faah and as faah imaging agents
2432012011592105/10/12 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
2442012010860005/03/12 Substituted 4-hydroxypyrimidine-5-carboxamides
2452012009500104/19/12 Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
2462012009505504/19/12 Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2472012008348304/05/12 Inhibitors of hepatitis c virus replication
2482012008267904/05/12 Antagonists of pcsk9
2492012008268004/05/12 Antagonists of pcsk9



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE